PDB59 TREATMENT PATTERNS AND GOAL ATTAINMENT FOR PATIENTS WITH TYPE 2 DIABETES  by Wisloff, TF et al.
diabetes knowledge, eating behavior score and BMI between
male and female were not signiﬁcantly different when controlling
for age (p > 0.05) however, calories burnt by exercise between
male and female patients were signiﬁcantly different (p < 0.05).
Partial correlation conﬁrmed that diabetes knowledge, calories
burnt by exercise and age were inversely signiﬁcantly correlated
to FBG (r = -0.51**, -0.36**, -0.28* with p < 0.01, p < 0.01,
p < 0.05 respectively). MRA model proved that ﬁve factors; dia-
betes knowledge, calories burnt by exercise, gender, age, and
BMI were the signiﬁcantly predictors of FBG (Beta= -0.40,
-0.25, -0.11, and -0.10 with p < 0.01, 0.01, 0.01, 0.05, 0.05,
R2 = 0.26). CONCLUSIONS: Diabetes knowledge, calories
burnt by exercise and gender were three signiﬁcantly most inﬂu-
ence factors for predicting Fasting Blood Glucose. The diabetes
patients should be educated on how to cope with diabetes and to
do the more exercise.
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OBJECTIVES: The goals of treatment for type 2 diabetes are to
prevent diabetic complications through intervention for hyperg-
lycaemia, hypertension and hyperlipidaemia. The aim of this
study was to describe the type of treatment patients receive and
their attainment of treatment goals in an unselected population
of patients with type 2 diabetes. METHODS: In 2007, 35 GP
centres in all areas of Norway (response rate 25%) had eight
types of data (including laboratory tests, drug prescriptions)
extracted from their electronic record systems for all patients
who had consulted for type 2 diabetes in 2000 or later. Data were
analysed with descriptive measures and regression techniques.
RESULTS: There has been a trend towards lower HbA1c values
since 2000, and 53% of the last recorded value was below 7%.
The proportion of patients with HbA1c value below 7% was
57% for patients on one oral antidiabetic drug, but 30% for
those on ﬁve drugs. At the last visit, 39% of the patients had
blood pressure below 135/85, and 36% of all patients were on
antihypertensive treatment. While 50% of patients without anti-
hypertensive drug had a blood pressure below 135/85, the pro-
portions were 36% for those on one drug and 35% fore those on
two drug. While the mean total cholesterol was 5.6 mmol/l in
2000, the value was 4.9 in 2007. At the last consultation, 51% of
the patients had a total cholesterol value below 5.0 mmoml/l.
CONCLUSIONS: In a general diabetes two population,
glyceamic control and lipid levels have improved over the last-
seven years. Use of multiple oral antidiabetics is an indicator of
poor glycaemic control.
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OBJECTIVES: To assess the management of severe hypoglycae-
mic events (SHEs) in Germany, Spain and the UK. METHODS:
A total of 639 adults with Type 1 (n = 319) or insulin-treated
Type 2 diabetes (n = 320), of median age 38 [range, 16–84] and
62 years [19–94], respectively, and with median diabetes dura-
tion of 16 [1–58] and 13 years [1–49], respectively, who had
experienced 1 SHEs (requiring external help for recovery) in
the preceding 12 months provided information on diabetes
history and SHE management by questionnaire. Patients were
grouped by where the SHE was treated: Group 1, community
(lay person); Group 2, community (health care professional);
Group 3, inside hospital. RESULTS: A total of 69% of patients
had >1 SHE/year (median, 2–3). Most events (69%) occurred
at home, mainly (74%) during the day (6 a.m.–10 p.m.), most
commonly because of insufﬁcient or irregular meals (45% of
patients). Most patients (168; 68%) had normal hypoglycaemia
awareness (Likert scale scores; not assessed in UK); impaired
hypoglycaemia awareness was commonest in Group 3 (17;
11.3%) and least common in Group 1 (11; 3.3%) (p = 0.003,
chi-square test). Hypoglycaemic coma was commonest in
Group 3 (58.7%) and least common in Group 1 (13.6%).
Coma prevalence was associated with impaired awareness
(p < 0.0001). More patients in Germany (58%) stayed in the
hospital for >24h than in Spain (16%) or the UK (28%)
(p < 0.0001). Following a SHE, more patients in Groups 2 and
3 than in Group 1 consulted their physician, tested blood
glucose more frequently, adjusted insulin dose and/or received
further education. Blood glucose tests increased by 2/day
(median) in the 4 weeks post-SHE and 293 (46%) patients
changed insulin dose. CONCLUSIONS: Other than duration of
in-patient stay, the frequency, cause and management of SHEs
were similar across countries despite cultural and health care
system differences. SHEs represent a substantial resource
burden on health care systems.
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OBJECTIVES: Both insulin detemir and insulin glargine have
been approved for reimbursement on the Australian Pharmaceu-
tical Beneﬁts Scheme (PBS). Prior to their listing, intermediate
acting insulin isophane (NPH) was the only PBS listed basal
insulin. Determination of the dose relativity from the randomised
clinical trials was confounded due to strict titration algorithms
and protocol requirements. Therefore to ascertain the dose rela-
tivity in clinical practice, a chart audit was conducted.
METHODS: The audit was carried out in six practices; ﬁve
specialist and one primary care. The inclusion criteria were:
diagnosis of type 1 diabetes, switched to detemir or glargine
between 01 October 2006 and 31 May 2007 and at least 6
months of follow-up. To ensure that there was no systematic
bias, the investigator was instructed to select every nth ﬁle with n
being a function of the number of patients who were eligible for
participation. RESULTS: Records were obtained on 87 patients
who switched to detemir and 77 patients who switched to
glargine. The baseline characteristics of patients were similar for
both groups with the exception that 30% (26/87) of patients
switched to detemir and 48% (37/77) of patients switched to
glargine were having once daily injections of NPH. Despite a
regulatory label for only once daily dosing for glargine, the audit
established that 25% of glargine use was twice daily. There was
no statistically signiﬁcant difference in baseline pre-switch NPH
doses to either detemir (0.44 to 0.45 U/kg/day) or glargine (0.45
to 0.43 U/kg/day). The dose relativity between detemir and
glargine ﬁnal doses was one to one. The audit also demonstrated
no statistically signiﬁcant difference in HbA1c between detemir
and glargine (8.0% & 7.8%, respectively). CONCLUSIONS:
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